Clinical Trial Detail

NCT ID NCT01787487
Title Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

myelofibrosis

chronic myelomonocytic leukemia

myelodysplastic/myeloproliferative neoplasm

atypical chronic myeloid leukemia

Therapies

Azacitidine + Ruxolitinib

Age Groups: adult senior

No variant requirements are available.